DBV Technologies S.A. (DBVT) fair value analysis
Nasdaq · Updated 2026-10-19
DBVT price how computed
Valuation status
No fair-value estimate yetDBVT has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for DBVT yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $9.05
- Sector
- Healthcare
- 12-month range
- $8.87–$24.54
- Market cap
- $569M
- From 52-week high
- -63.1%
- Shares outstanding
- 62.8M
- Rank in Healthcare by quality score
- #233 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
DBV Technologies S.A. is a biopharmaceutical company that develops and commercializes therapeutic products, with a focus on immunotherapy treatments. The company is headquartered in France and operates in multiple countries including the United States and Europe.
DBVT currently ranks #233 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $569M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-1.10
- Debt / equity
- 0.13
- Revenue growth (3-yr avg)
- -33.3%
- Shares outstanding
- 62.8M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 22 · oversold
- 50-day average
- $12.41
- 200-day average
- $17.34
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-10-27
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-400.0%)
2026-03 ▲ beat (+25.0%)
2025-12 ▼ miss (-5.7%)
2025-09 ▲ beat (+27.6%)
2025-06 ▼ miss (-68.8%)
2025-03 ▼ miss (-4.5%)
2024-12 ▼ miss (-1.2%)
2024-09 ▲ beat (+9.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 0 hold · 1 sell (6 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $38.6
- Target vs last price
- +326.5%
What our data shows for DBVT
- Shares are trading in the lower third of their 12-month price range of $8.87–$24.54.
- The 14-day relative strength index sits at an oversold 22.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- DBVT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the DBVT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — DBVT in the Healthcare sector experienced a shift in its RSI zone this week, moving from neutral territory into oversold conditions according to TickrTrends' derived indicators. This technical movement suggests increased downward momentum in the stock's recent price action. The valuation assessment remains in a pending state pending completion of the full valuation analysis.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is DBVT stock undervalued?
TickrTrends has no fair-value estimate for DBVT yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is DBVT's TickrTrends verdict?
DBVT is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does DBVT compare to other Healthcare stocks?
DBVT ranks #233 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is DBVT overbought or oversold?
DBVT's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does DBVT report earnings next?
DBVT's next earnings report is scheduled for 2026-10-27, per the published earnings calendar.
Does DBVT usually beat earnings estimates?
Over its last 8 reported quarters DBVT beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about DBVT?
Of 6 analysts covering DBVT, 5 rate it a buy, 0 a hold and 1 a sell - buy-leaning, with a consensus price target of $38.6 (+326.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.